Dr. Reddy's Laboratories Ltd.
recently announced the U.S. Food and Drug Administration (FDA)
approval of its bioequivalent generic version of
) Vidaza. The generic will be launched soon.
Vidaza is approved for the treatment of patients with some of
the French-American-British myelodysplastic syndrome subtypes:
refractory anemia or refractory anemia with ringed sideroblasts,
refractory anemia with excess blasts, refractory anemia with
excess blasts in transformation, and chronic
myelomonocyticleukemia. According to IMS Health, Vidaza generated
U.S. revenues of approximately $378.5 million MAT (moving annual
total) in the 12 months ending Jul 2013.
Revenues at Dr. Reddy's Global Generics segment were up 15% to
$368 million in the first quarter ended Jun 30, 2013. Strong
sales in North America and emerging markets led to the growth at
the Global Generics division. Generics revenues increased in
North America (up 37%), Russia and other CIS (Commonwealth of
Independent States) markets (up 8%), and the rest of the world,
or RoW (up 12%).
Dr. Reddy's launched 23 new generic products, filed 12
registrations for new products and also filed 5 drug master files
(DMFs) globally in the first quarter of 2014.
During the first quarter of fiscal 2014, Dr. Reddy's filed 2
abbreviated new drug applications (ANDAs) with the FDA. As of Jul
30, 2013, Dr. Reddy's had 64 ANDAs pending approval with the FDA,
of which 38 are Para IV filings and 8 are first-to-file.
Dr. Reddy's carries a Zacks Rank #5 (Strong Sell).
) appear to be well placed in the generic space with a Zacks
Rank #2 (Buy).
ACTAVIS INC (ACT): Free Stock Analysis Report
AKORN INC (AKRX): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis
DOCTOR REDDYS (RDY): Free Stock Analysis
To read this article on Zacks.com click here.